ViviGen Cellular Bone Matrix Outperforms MSC-based Allografts and is Equivalent to Gold Standard Autograft According to Recent Peer-Reviewed Publications
"These studies are an exciting advancement of our knowledge of ViviGen," said Mark Moore, PhD, Chief Scientific Affairs Officer at LifeNet Health. "We developed ViviGen based on pre-clinical research that showed a cellular graft focused on viable, lineage-committed bone cells could result in a safe, clinically effective bone void filler.